Metabolism Driving Cell Death and Inflammation in Alzheimer’s Disease

Using directly induced neurons from patient skin cells, we will investigate how PKM isoforms regulate neuronal resilience to cell death, and pro-inflammatory signatures in Alzheimer’s disease neurons.

Aim 1: A gain of nuclear PKM2 and the loss of cytosolic PKM1 function are concerted driving mechanism in neurodegeneration, but the relative importance of the two phenomena is still unclear. We will engineer PKM2 to better understand PKM changes in AD neurons with regard to intervention strategies. Aim2: We will establish co-culture models containing healthy and diseased neurons and astrocytes to define neuron-glia interactions, the inflammatory phenotypes of astrocytes, and the reversibility of neuroinflammation, which we hypothesize originates in neurons, by treatments with PKM modulators.

We hypothesize that a cancer-like isoform switch between PKM1 and PKM2 drives neuronal fate loss in Alzheimer neurons and thus re-instates neuronal cell death competency, which is a novel concept in the AD field. Our goal is to open new possibilities for Alzheimer therapeutics. Importantly, several PKM modulators are already in clinical trials as cancer therapeutics, and have been shown to restore some aspects of the AD phenotype in AD neurons. This study will enhance the understanding of PKM isoforms in neurons to enhance targeted development of PKM modulators for the treatment of AD. Currently, there are no drugs that can stop or reverse Alzheimer’s disease progression. We identified a novel mechanism that drives neuronal de-differentiation, where the re-gain developmental features, such as their competency to die, and is partly driven by the isoform switch of PKM. With the results of this project, we aim to enhance the targeted generation of efficient PKM modulators to address the AD-specific mechanism in post-mitotic neurons to render neurons more resilient and prevent neurodegeneration.

Grantee institution at the time of this grant: University of Innsbruck

We hypothesize that a cancer-like isoform switch between PKM1 and PKM2 drives neuronal fate loss in Alzheimer neurons and thus re-instates neuronal cell death competency, which is a novel concept in the AD field. Our goal is to open new possibilities for Alzheimer therapeutics. Importantly, several PKM modulators are already in clinical trials as cancer therapeutics, and have been shown to restore some aspects of the AD phenotype in AD neurons. This study will enhance the understanding of PKM isoforms in neurons to enhance targeted development of PKM modulators for the treatment of AD.

Currently, there are no drugs that can stop or reverse Alzheimer’s disease progression. We identified a novel mechanism that drives neuronal de-differentiation, where the re-gain developmental features, such as their competency to die, and is partly driven by the isoform switch of PKM. With the results of this project, we aim to enhance the targeted generation of efficient PKM modulators to address the AD-specific mechanism in post-mitotic neurons to render neurons more resilient and prevent neurodegeneration.